期刊文献+

过氧化物酶体增殖物激活受体γ在垂体腺瘤中的表达 被引量:1

Correlation of peroxisome proliferation - activated receptor in pituitary adenoma
原文传递
导出
摘要 目的通过检测过氧化物酶体增殖物激活受体γ(PPARγ)在人垂体腺瘤组织中的表达,探讨其在垂体腺瘤中的相关机制。方法通过免疫组化法确定经手术切除的83例垂体腺瘤组织细胞来源;采用RT—PCR、适时定量PCR检测研究83例垂体腺瘤组织及6例正常垂体组织PPA脚的mRNA表达量,采用Western blot法检测组织PPARγ蛋白质表达水平,分析不同类型垂体腺瘤组织之间核酸及蛋白水平表达量的差异。结果GH腺瘤17例、PRL腺瘤15例、ACTH腺瘤18例、多激素腺瘤(MCPAs)17例、无功能腺瘤(NFAs)16例及正常对照组6例;mRNA水平检测显示所有垂体腺瘤组织的表达量均高于正常对照组,其中GH腺瘤的表达量最高,与其他组比较P〈0.05;蛋白水平检测显示GH腺瘤、PRL腺瘤、ACTH腺瘤及MCPAs的表达量均高于正常对照组(P〈0.05),GH腺瘤的表达量最高,NFAs的表达量与正常对照组差异无统计学意义(P〉0.05)。结论PPARγ转录及蛋白表达水平在人GH、PRL、ACTH及MCPAs垂体腺瘤组织中高表达,该基因与垂体腺瘤有一定的相关性,而无功能垂体腺瘤在核酸水平的表达量增高,蛋白水平的表达量不高,可能与激素的分泌水平有关;在GH腺瘤中的表达量最高,且与其他组相比,差异有统计学意义(P〈0.05),说明该类肿瘤与PPARγ的关系最为密切,可能与生长激素能刺激PPARγ的表达有关。 Objective To prove the expression of PPARγ in human pituitary adenomas, and administrate that the expression among different tumors has significant difference. Method 83 cases of pituitary adenoma tissues and 6 normal pituitary tissues were divided into different groups by immunohisehemical according to the source of tissues and cells. The mRNA of PPARγ in 83 pituitary adenomas tissues and 6 normal pituitary tissues were determined by RT - PCR and quantitative real - time PCR, the protein of PPARγ were detected by western - blot. Result we have 89 samples, 17 samples tested as GH secreting- adenomas, 15 samples tested as PRL secreting- adenomas, 18 samples tested as ACTH secreting- adenomas, 17 samples tested as miscellaneous pituitary adenomas (MCPAs) , 16 samples tested as nonfunctional pituitary adenomas ( NFAs ) and 6 samples tested as normal ; the PPARγ mRNA expressions were higher in all kinds of pituitary adenomas than in the normal pituitary tissue. GH secreting - adenomas was the highest, and the differentia was significant in statistics ; the protein expression level of PPARγ in GH secreting, Prolaetin secreting, ATCH secreting and MCPAs were higher than in the normal pituitary tissue ( P 〈 0. 05 ), and the expression in GH secreting- adenomas was the highest which has markedly differentia. The expression level of NFAs has no different compared with normal pituitary ( P 〉 0. 05 ). Conclusion We supposed that PPARγ is an important molecular target in pituitary adenoma cells, especially for GH secreting -adenomas.
出处 《中华神经外科杂志》 CSCD 北大核心 2009年第10期893-896,共4页 Chinese Journal of Neurosurgery
基金 基金项目:国家自然科学基金资助项目(30672161,39670736)
关键词 过氧化物酶体增殖物激活受体Γ 垂体腺瘤 生长激素腺瘤 无功能垂体腺瘤 PPARγ Pituitary adenoma GH secreting - adenoma Nonfunctioning pitultary adenoma
  • 相关文献

参考文献10

  • 1张晖,程惊秋,黄强,杨静,沈彬,周宗科,康鹏德,廉永云,裴福兴.瞬时干扰PPARγ基因促进酒精诱导下人骨髓基质干细胞成骨分化的实验研究[J].中华医学杂志,2008,88(37):2603-2608. 被引量:6
  • 2陶帮宝,郭新宾,卞留贯,孙青芳,杨明,周岩方,牟朝辉.PPARγ在垂体腺瘤组织中的表达及意义[J].中国实验诊断学,2008,12(1):80-82. 被引量:2
  • 3环奕,申竹芳.选择性PPARγ调节剂治疗糖尿病的研究新进展[J].中国药理学通报,2008,24(2):149-152. 被引量:11
  • 4Janssen JA,Lamberts SW.Circulating IGF-I and its protective role in the pothogenesis of diabetic angiopathy.Clin Endocrinol,2000,52:1-12.
  • 5黄灵芝.PPARα和PPARγ双重激动剂用于治疗2型糖尿病和代谢综合征[J].国外医学:药学分册,2007,34:151-152.
  • 6Paez-Pereda M,Giacomini D,Echenique C,et al.Signaling processes in tumoral neuroendocrine pituitary cells as potential targets for therapeutic drugs.Curr Drug Targets Immune Endocr Metabol Disord,2005,5:259-267.
  • 7Vidal-Puig A,Considine RV,Jimenez.Linan M,et al.Peroxisome proliferator-activated receptor gene expression in human tissues.Effects of obesity,weight loss,and regulatin by insulin and glueocorticoids.J Clin Invest,1997,99:2416-2422.
  • 8Heaney AP,Femando M,Yong WH,et al.Functional PP-AR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas.Nature Med,2002,8:1281-1287.
  • 9王嵘,史继新,蒋健,刘承基,印红霞,吴波.人垂体腺瘤中的细胞凋亡[J].中华神经外科杂志,2005,21(3):146-148. 被引量:3
  • 10Barz T,Hoffmann A,Panhuysen M,et al.Peroxisome proliferatoractivated receptor gamma is a Zac target gene mediating Zac antiproliferation.Cancer Res,2006,66:11975-11982.

二级参考文献65

  • 1徐剑,史轶蘩.过氧化物酶体增殖物激活受体γ与肥胖[J].国外医学(内分泌学分册),2004,24(6):381-383. 被引量:4
  • 2陈娜,吴英良.PPARδ的结构及其生物学功能与疾病[J].中国药理学通报,2006,22(9):1035-1038. 被引量:11
  • 3Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult hmnan mesenchymal stem cells. Science, 2000 ,284:143- 147.
  • 4Oreffo ROC, Cooper C, Mason C, et al. Mesenchymal stem cells : lineage, plasticity and skeletal therapeutic potential. Stem Cell Rev,2005 ,103:1169-1178.
  • 5NuttaU ME, Patton AJ, Olivera DL, et al. Human trabecular bone ceils are able to express both osteoblastic and adipogenic phenotype: implications for osteopenic disorders. J Bone Miner Res,2000 ,13:371-382.
  • 6Brown EC, Perrien DS, Fletcher TW, et al. Skeletal toxicity associated with chronic ethanol exposure in a rat model using total enteral nutrition. J Pharmacol Exp Ther,2002,301 : 1132-1138.
  • 7Chakkalakal DA. Alcohol-Induced bone loss and deficient bone repair alcohol. Clin Exp Res, 2005, 29:2077-2090.
  • 8Wezeman FH, Gong Z. Adipogenic effect of alcohol on human bone marrow-derived mesenchymal stem cells. Alcohol Clin Exp Res,2004, 28:1091-1101.
  • 9Klein RF. Alcohol-induced bone disease: impact of ethanol on osteoblast proliferation. Alcohol Clin Exp Res , 1997, 21:392- 399.
  • 10Eriksen JL, Druse MJ. Potential involvement of S100B in the protective effects of a serotonin-1 A agonist on ethanol treated astrocytes. Dev Brain Res,2001, 128:157-164.

共引文献18

同被引文献26

  • 1毛志钢,王海军,朱永红,何东升,蓝海,徐伟光,冯雷.垂体生长激素腺瘤病人术前应用奥曲肽的初步研究[J].中国微侵袭神经外科杂志,2006,11(9):396-398. 被引量:4
  • 2Feelders RA, Hofland LJ, van Aken MO, et al. Medical therapy of acromegaly: efficacy and safety of somatostatin analogues. Drugs ,2009, 69:2207-2226.
  • 3Ben-Shlomo A, Melmed S. Pituitary somatostatin receptor sign- aling. Trends Endocrinol Metab,2010, 21:123-133.
  • 4Taboada GF, Luque RM, Bastos W, et al. Quantitative analysis of somatostatin receptor subtype (SSTR1 5 ) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol, 2007, 156:65-74.
  • 5Bevan JS. The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab,2005, 90:1856-1863.
  • 6Grozinsky-Glasberg S, Shimon I, Korbonits M, et al. Soma- tostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocr Relat Cancer, 2008, 15: 701-720.
  • 7Zelija VA. The efficacy of octreotide LAR in acromegalic patients as primary or secondary therapy. Ther Adv Endocfinol Metab, 2012 , 3: 3-9.
  • 8Sherlock M, Woods C, Sheppard MC. Medical therapy in acro- megaly. Nat Rev Endocrinol,2011, 7:291-300.
  • 9Colao A, Auriemma RS, Galdiero M, et al. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocrinol Metab, 2009, 94:3746-3756.
  • 10Carlsen SM, Lund-Johansen M, Sehreiner T, et al. Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab, 2008, 93:2984-2990.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部